AirSculpt Technologies, Inc. (AIRS) Q2 2025 Earnings Call Transcript

AirSculpt Technologies (NASDAQ:AIRS) reported Q2 2025 revenue of $44 million, down 13.7% year-over-year, and Adjusted EBITDA of $5.8 million, attributing declines to a challenging consumer environment despite record lead growth. The company noted sequential improvements in revenue trends and significantly reduced customer acquisition costs to $2,905 per case, reflecting early benefits from strategic initiatives like reallocated marketing and expanded financing options. AirSculpt strengthened its balance sheet by repaying $16 million in debt, improving its leverage ratio to 2.87x. Management reiterated its full-year 2025 revenue guidance of $160-$170 million and Adjusted EBITDA of $16-$18 million, emphasizing a focus on improving existing same-store sales with no new center openings planned, while CFO Dennis Dean announced his retirement.

Analysis

AirSculpt Technologies (AIRS) reported a challenging second quarter, with revenue declining 13.7% year-over-year to $44 million and adjusted EBITDA falling to $5.8 million. The weakness was driven by a 14.1% drop in case volume, reflecting a persistent softness in consumer discretionary spending and a significant 22% decline in same-store revenue. Despite these headwinds, the company demonstrated early signs of a strategic turnaround. Management highlighted a sequential moderation in the revenue decline by four percentage points from Q1 and record lead generation, suggesting strong underlying consumer interest. Crucially, operational efficiency improved, evidenced by the first year-over-year decrease in customer acquisition cost (CAC) since the IPO, which fell to $2,905 per case from $3,325. The company also fortified its balance sheet, using proceeds from a follow-on offering and cash from operations to repay $16 million in debt, reducing its leverage ratio to 2.87x from 3.76x in the prior quarter. Management reiterated its full-year 2025 guidance for revenue of $160-$170 million and adjusted EBITDA of $16-$18 million, implying a stabilization in the second half. This outlook is predicated on the success of initiatives like expanded financing options, which are now used by 50% of patients, and a new skin-tightening pilot, though it excludes new center openings and faces uncertainty from the announced retirement of its CFO.

Key Decisions for Investors

• Investors should closely monitor lead conversion rates and same-store sales trends in the second half, as these are the primary indicators of whether the company's strategic initiatives are successfully translating high consumer interest into revenue.
• The improved balance sheet and reduced leverage ratio of 2.87x mitigates financial risk, but the ongoing CFO transition introduces execution uncertainty that warrants close observation.
• While the reiterated full-year guidance suggests a potential inflection point, investors must weigh the early operational improvements, like lower customer acquisition costs, against the persistent macroeconomic pressures on consumer spending.
• Consider the un-modeled upside from new initiatives, such as the skin-tightening pilot aimed at capitalizing on the GLP-1 trend, but recognize these are in early stages and success is not yet reflected in financial forecasts.